How much funding has Vima Therapeutics raised?

Vima Therapeutics has raised $40.0M in total funding, most recently a Series A round.

Who are Vima Therapeutics's investors?

Vima Therapeutics's investors include Frazier Healthcare, Atlas Venture, Canaan Partners, Access Industries.

When was Vima Therapeutics founded?

Vima Therapeutics was founded in 2025.

Where is Vima Therapeutics headquartered?

Vima Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Vima Therapeutics in?

Vima Therapeutics operates in Biotech, Healthcare.

How many employees does Vima Therapeutics have?

Vima Therapeutics has 1-10 employees.

Vima Therapeutics

Freedom to move

Cambridge, United States · Founded 2025 · $40.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 1–10
Founded: 2025
Business Model: B2B

Website: vimatx.com
Total Funding: $40.0M
Last Round: $40.0M Series AMar 2026
Rounds: 1

About

Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders. The company is developing a novel oral therapy designed to help patients regain control of movement by targeting the underlying biology of disease. Dystonia is a chronic, disabling movement disorder affecting both adults and children with no cure, sharing biology with Parkinson's disease and dystonic cerebral palsy — conditions that together affect more than one million people in the United States. Founded by neurologist Dr. Bernard Ravina in partnership with Atlas Venture, Vima launched in May 2025 with $60 million in Series A financing and is headquartered in Cambridge, Massachusetts.

Summary

Vima Therapeutics is a Biotech company based in Cambridge, United States, founded in 2025. It has raised $40.0M in total across 1 round, most recently a $40.0M Series A round in Mar 2026. Investors include Frazier Healthcare, Atlas Venture and Canaan Partners.